tetrandrine has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; Duan, Y; Fu, Y; Geng, M; Hu, Y; Huang, M; Lan, X; Pu, C; Shen, N; Tang, S; Wang, X; Xu, J; Yuan, L; Yuan, T; Zheng, Y; Zhou, Y; Zhu, H | 1 |
1 other study(ies) available for tetrandrine and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis.
Topics: Benzylisoquinolines; Carcinoma, Pancreatic Ductal; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptors, Death Domain | 2023 |